In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors.
about
An indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of Type III virulence phenotypes of Pseudomonas aeruginosa isolates.Bacterial Sphingomyelinases and Phospholipases as Virulence FactorsAssociation between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a reviewA surface phospholipase is involved in the migration of plasmodium sporozoites through cellsIntoxication of host cells by the T3SS phospholipase ExoU: PI(4,5)P2-associated, cytoskeletal collapse and late phase membrane blebbingStructural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosaStructure of the Type III Secretion Effector Protein ExoU in Complex with Its Chaperone SpcUCooperative Substrate-Cofactor Interactions and Membrane Localization of the Bacterial Phospholipase A2 (PLA2) Enzyme, ExoU.Pseudomonas aeruginosa induces localized immunosuppression during pneumoniaCloning and characterization of the gene encoding the major cell-associated phospholipase A of Legionella pneumophila, plaB, exhibiting hemolytic activity.Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU.The hemolytic and cytolytic activities of Serratia marcescens phospholipase A (PhlA) depend on lysophospholipid production by PhlA.Activation of ExoU phospholipase activity requires specific C-terminal regions.Functional regions of the Pseudomonas aeruginosa cytotoxin ExoUA sensitive fluorescence-based assay for the detection of ExoU-mediated PLA(2) activity.Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infectionCharacterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU.Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia.Characterization of the major secreted zinc metalloprotease- dependent glycerophospholipid:cholesterol acyltransferase, PlaC, of Legionella pneumophila.Pathogen effector protein screening in yeast identifies Legionella factors that interfere with membrane traffickingFunctional characterization of a phospholipase A(2) homolog from Rickettsia typhi.Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicityInduced conformational changes in the activation of the Pseudomonas aeruginosa type III toxin, ExoU.Members of a Legionella pneumophila family of proteins with ExoU (phospholipase A) active sites are translocated to target cells.Transcriptional induction of the Pseudomonas aeruginosa type III secretion system by low Ca2+ and host cell contact proceeds through two distinct signaling pathways.Rickettsia typhi possesses phospholipase A2 enzymes that are involved in infection of host cells.Ubiquitin activates patatin-like phospholipases from multiple bacterial speciesEmergence of a bacterial clone with enhanced virulence by acquisition of a phage encoding a secreted phospholipase A2.The Rickettsia prowazekii ExoU homologue possesses phospholipase A1 (PLA1), PLA2, and lyso-PLA2 activities and can function in the absence of any eukaryotic cofactors in vitroUbiquitin and ubiquitin-modified proteins activate the Pseudomonas aeruginosa T3SS cytotoxin, ExoU.Process of protein transport by the type III secretion systemIron-Regulated Phospholipase C Activity Contributes to the Cytolytic Activity and Virulence of Acinetobacter baumannii.Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome.Pseudomonas aeruginosa exoenzymes U and Y induce a transmissible endothelial proteinopathyMultiple roles of phospholipase A2 during lung infection and inflammation.A novel sensor kinase-response regulator hybrid regulates type III secretion and is required for virulence in Pseudomonas aeruginosaPhosphatidylinositol 4,5-bisphosphate is a novel coactivator of the Pseudomonas aeruginosa cytotoxin ExoU.Identification of the major ubiquitin-binding domain of the Pseudomonas aeruginosa ExoU A2 phospholipase.Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.The type III secretion system of Pseudomonas aeruginosa: infection by injection.
P2860
Q25256862-2050B8FF-A4F4-4EDD-880F-70CA9C257F84Q26745804-B5B9E783-8094-487E-8130-20EF81C3F852Q27013824-87904139-3E85-4793-9972-0051C1B0F675Q27230058-456B01AF-1B7D-450D-B40D-D625D723ABBBQ27318150-4B8893D9-30DD-4531-9368-EBA7A5AEF13DQ27346512-5A0F3C4D-784E-47DA-8036-24E94D802DB5Q27675175-2633641A-9558-4441-A3A9-3A975C052C90Q30397248-AE83E620-BDB5-4EBF-A1C4-315305A9922EQ30483670-40A6C552-0791-487D-BEE0-33DB99617EE4Q33202129-87B171B8-5D8E-4E57-B4CA-D215DF579473Q33267063-085E1855-E831-4DE5-AA1E-20FE984222A7Q33518058-24CFD79F-98F6-4611-BE27-FD5239C4FEFEQ33526200-CE2AEBAF-9518-479E-8031-929D4A09A257Q33558698-0B36F412-2E94-454C-9C13-80790594EBD2Q33615801-28A7525C-680B-45CE-B8C4-81A6128696AEQ33716022-4D78881A-972C-4BED-934D-09BABBD31AF9Q33758218-D5784F29-3000-4B35-8CDC-C658CCC1F9E7Q33769046-CDE5C3DB-9644-4E24-B8AC-DA35679A8293Q33769080-2722389F-96F9-4DA0-9254-FD4C718883EDQ33935172-B2058695-43C7-4B5B-8F8A-59C855EFA509Q33964188-85C80147-374A-491E-ADAD-CF393F653C73Q34045056-802C090C-D3E9-4E0D-B432-6FB37A397B61Q34594672-FE4D4A4A-1BA3-40B2-8CFD-BB67180E15A8Q34680988-2656147D-392D-4996-953C-8C149E2CD6A8Q34681186-274B4C31-D2EB-40B2-A6CF-32294FC76047Q34789261-6DF24A57-5BBE-47D7-BCA7-90E11F9BC607Q34853536-8AA1B98F-D046-4358-95D8-E37DE2DEB5A3Q35127605-0D88A482-2B8C-45A9-9C03-F265EB23953EQ35192583-7BF9BAB6-AC93-4F61-84F3-E94934CE201BQ35613242-B37980CF-925C-4220-AB84-367D3D6F89C4Q35980175-3D9E9E05-C923-498F-BDD0-915AEED9A85EQ36201175-1614693D-B1D4-4362-A596-9B8CA8A55648Q36294419-338336BF-66FE-4D8A-8641-025769695203Q36583852-840FDF47-7CD6-4856-BFB5-1BF87E23FECEQ36710691-5D90B3CD-C130-4BDD-B114-F4B7B173BF1EQ36833622-10C7B7B7-14B1-45BB-9810-D6C9C4318CE2Q37036010-EEA1C4C0-37D2-40E2-B7D5-C95DBF5F6A9CQ37168437-BD1E34AA-E393-4F3D-A495-CA3F35F33AFBQ37358382-7B4158D3-8EDD-4C5B-AF18-44E2CB3E4A14Q37397923-50BCD221-5451-4830-A98F-46D610D811C8
P2860
In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
In vivo phospholipase activity ...... h phospholipase A2 inhibitors.
@en
In vivo phospholipase activity ...... h phospholipase A2 inhibitors.
@nl
type
label
In vivo phospholipase activity ...... h phospholipase A2 inhibitors.
@en
In vivo phospholipase activity ...... h phospholipase A2 inhibitors.
@nl
prefLabel
In vivo phospholipase activity ...... h phospholipase A2 inhibitors.
@en
In vivo phospholipase activity ...... h phospholipase A2 inhibitors.
@nl
P2860
P50
P356
P1476
In vivo phospholipase activity ...... h phospholipase A2 inhibitors.
@en
P2093
Partho Ghosh
P2860
P304
41326-41332
P356
10.1074/JBC.M302472200
P407
P577
2003-08-12T00:00:00Z